

April 12, 2017

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East,
Mumbai-400051

Dear Sir/Madam,

Sub: Clarification/Confirmation on news item appearing in "Media/Publication"

We refer to your letter no. NSE/CM/Surveillance/6734 dated April 12, 2017 seeking clarification on news item that appeared in ET Now, captioned "Jubilant Life to acquire cancer & body imaging company in US. Acquisition to be done via unit Jubilant Draximage Inc."

In this regard, please be informed that we have already announced to the Stock Exchanges on March 21, 2017 that the Board of Directors of Jubilant Pharma Limited ("JPL"), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.

As informed earlier, the Company is still in negotiation stage and if the negotiations materialise, we shall disclose the same to the Stock Exchanges in compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

At this juncture, the Company does not have anything more to disclose to the Stock Exchanges.

Thanking You,

Yours Faithfully,
For Jubilant Life Sciences Limited



Rajiv Shah
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624